181990

Scientific and Technical Information Center

SEARCH: REQUEST FORM

611	· m	7/2	2/10/06
Requester's Full Name: Sobolis Art Unit:	a (197)	Examiner # : <u> </u>	Date: 3/10/06
Art Unit: 1616 Phone N	umber: <u>7-0622</u>	Serial Number: 10	7 3 70; 03 F
Location (Bldg/Room#):	ailbox #): 46 fb R6	esults	**************************************
To ensure an efficient and quality search, ple			fill out the following:
Title of Invention: Fung	riides		
Title of Invention:	CRONLE	y et-l	
		•	
Earliest Priority Date: 12/23/	102 3718	PCT/GB03/0	5148.
Search Topic: Please provide a detailed statement of the sear elected species or structures, keywords, synony Define any terms that may have a special mean	ch topic, and describe as speci	ifically as possible the subject mo umbers, and combine with the co	atter to be searched. Include the ' oncept or utility of the invention.
For Sequence Searches Only Please includ	e all pertinent information (po	arent, child, divisional, or issued	patent numbers) along with the
appropriate serial number.	- 10+11-12	1.	
Please bear		e compos	of formula
· el 1.	. 0	:1.	- WX + Y are CI
1 m cl 1.		Whe	· 1/
	R,	a E	·s N·
	1 Total	•	
	70.	2	4 / 1
	0 1	be NR3R	where
Note that R3 + R4 Can buch as	R, es	be NR3R	enclu gf.
Note	1 km	on helest	
R + R. Com	~ aiso D	in Thisame	replication -
3 4	morphani		
bulh	/	·	
J. 10. 1		, I the	et-
01 8	ce alla	eled She	
Please			·
:			
			·
Thank of	1m		
	,		
*******	*****	******	******
STAFF USE ONLY	Type of Search		t where applicable
Searcher:	NA Sequence (#)	STN	
Searcher Phone #:	AA Sequence (#)		rbit Lexis/Nexis
Searcher Location:	Structure (#)	Westlaw	WWW/Internet
Date Searcher Picked Up:	Bibliographic	In-house seq	uence systems
Data Completed	Litigation	CommercialInterference	Oligomer Score/Length Encode/Transl
Date Completed:		0	ther (specify)
'Searcher Prep & Review Time:	Other		•
Online Time:	 ·		

```
=> d his ful
```

(FILE 'HOME' ENTERED AT 15:17:04 ON 23 MAR 2006)

FILE 'REGISTRY' ENTERED AT 15:17:10 ON 23 MAR 2006
L1 STR
L2 STR
L3 0 SEA SSS SAM L1 AND L2
L4 4 SEA SSS FUL L1 AND L2
D SCA
FILE 'HCAPLUS' ENTERED AT 15:18:55 ON 23 MAR 2006

FILE 'HCAPLUS' ENTERED AT 15:18:55 ON 23 MAR 2006 L5 2 SEA ABB=ON PLU=ON L4 E US2005-540037/APPS E WO2003-GB5248/APPS

L6 1 SEA ABB=ON PLU=ON (WO2003-GB5248/AP OR WO2003-GB5248/PRN)

FILE 'BEILSTEIN' ENTERED AT 15:20:23 ON 23 MAR 2006

L9 0 SEA SSS SAM L1 AND L2 L10 3 SEA SSS FUL L1 AND L2

L11 0 SEA ABB=ON PLU=ON L10/COM

FILE 'MARPAT' ENTERED AT 15:22:22 ON 23 MAR 2006

L12 25 SEA SSS SAM L1 L13 550 SEA SSS FUL L1 L14 5 SEA SUB=L13 SSS 3

L14 5 SEA SUB=L13 SSS SAM L2 L15 97 SEA SUB=L13 SSS FUL L2

7 SEA SUB=L13 SSS FUL L2 D QHIT

L16 97 SEA ABB=ON PLU=ON L15/COM

L17 STR L1

L18 12 SEA SUB=L13 SSS FUL L17

L19 10 SEA ABB=ON PLU=ON L18 NOT L5

FILE HOME

FILE REGISTRY

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 21 MAR 2006 HIGHEST RN 877591-95-2 DICTIONARY FILE UPDATES: 21 MAR 2006 HIGHEST RN 877591-95-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

* The CA roles and document type information have been removed from * the IDE default display format and the ED field has been added, * effective March 20, 2005. A new display format, IDERL, is now * available and contains the CA role and document type information. *

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

FILE HCAPLUS

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 23 Mar 2006 VOL 144 ISS 13 FILE LAST UPDATED: 22 Mar 2006 (20060322/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE BEILSTEIN
FILE LAST UPDATED ON MARCH 15, 2006

FILE COVERS 1771 TO 2006.
FILE CONTAINS 9,516,393 SUBSTANCES

>>>PLEASE NOTE: Reaction Data and substance data are stored in separate documents and can not be searched together in one query. Reaction data for BEILSTEIN compounds may be displayed immediately with the display codes PRE (preparations) and REA (reactions). A substance answer set retrieved after the search for a chemical name, a compounds with available reaction information by combining with PRE/FA, REA/FA or more generally with RX/FA. The BEILSTEIN Registry Number (BRN) is the link between a BEILSTEIN compound and belonging reactions. For mo detailed reaction searches BRNs can be searched as reaction partner BRNs Reactant BRN (RX.RBRN) or Product BRN (RX.PBRN).<<<

>>> FOR SEARCHING PREPARATIONS SEE HELP PRE <<<

NEW

- * PATENT NUMBERS (PN) AND BABS ACCESSION NUMBERS (BABSAN) CAN NOW BE SEARCHED, SELECTED AND TRANSFERRED.
- * NEW DISPLAY FORMATS ALLREF, ALLP AND BABSAN SHOW ALL REFERENCES, ALL PATENT REFERENCES, OR ALL BABS ACCESSION NUMBERS FOR A COMPOUND AT A GLANCE.

FILE MARPAT

FILE CONTENT: 1961-PRESENT VOL 144 ISS 12 (20060317/ED)

SOME MARPAT RECORDS ARE DERIVED FROM INPI DATA FOR 1961-1987

MOST RECENT CITATIONS FOR PATENTS FROM MAJOR ISSUING AGENCIES (COVERAGE TO THESE DATES IS NOT COMPLETE):

```
2006035965 16 FEB 2006
US
DE 102004030305 12 JAN 2006
        1614691 11 JAN 2006
EΡ
JΡ
     2006008639 12 JAN 2006
     2006012333 02 FEB 2006
WO
GB
        2415429 28 DEC 2005
FR
        2873371 27 JAN 2006
RU
        2267521 10 JAN 2006
        2472818 30 DEC 2005
CA
```

Expanded G-group definition display now available.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

=> fil hcap FILE 'HCAPLUS' ENTERED AT 15:25:41 ON 23 MAR 2006 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

```
FILE COVERS 1907 - 23 Mar 2006 VOL 144 ISS 13 FILE LAST UPDATED: 22 Mar 2006 (20060322/ED)
```

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
=> d que stat 15
L1 STR
```



NODE ATTRIBUTES:

CONNECT IS E2 RC AT 1
CONNECT IS E2 RC AT 2
CONNECT IS E2 RC AT 6
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED NUMBER OF NODES IS 10

STEREO ATTRIBUTES: NONE L2 STR



NODE ATTRIBUTES:

NSPEC IS RC AT 3
CONNECT IS M2 RC AT 3
DEFAULT MLEVEL IS ATOM
GGCAT IS PCY UNS AT 2
DEFAULT ECLEVEL IS LIMITED
ECOUNT IS E8 C E2 N AT

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED NUMBER OF NODES IS 4

STEREO ATTRIBUTES: NONE

4 SEA FILE=REGISTRY SSS FUL L1 AND L2 L5 2 SEA FILE=HCAPLUS ABB=ON PLU=ON L4

=> d 15 ibib abs hitstr 1-2

L5 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:99502 HCAPLUS

DOCUMENT NUMBER: 142:198091

TITLE: Preparation of pyridopyridines and pyridopyrimidines

as agrochemical fungicides.

INVENTOR(S): Wagner, Oliver; Grote, Thomas; Blettner, Carsten;

Gewehr, Markus; Grammenos, Wassilios; Gypser, Andreas; Mueller, Bernd; Rheinheimer, Joachim; Schaefer, Peter; Schieweck, Frank; Schwoegler, Anja; Tormo, I. Blasco

Jordi; Akers, Alan; Speakman, John-Bryan; Rack,

Michael; Stierl, Reinhard; Scherer, Maria; Strathmann,

Siegfried; Schoefl, Ulrich

PATENT ASSIGNEE(S): BASF Aktiengesellschaft, Germany

SOURCE: PCT Int. Appl., 60 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

GΙ

PA'	PATENT NO.					Ď	DATE			APPL	ICAT	ION	NO.		D.	ATE	
WO	2005	0100	00		A2	_	2005	0203	1	WO 2	004-	EP79:	24		2	0040	715
WO	2005	0100	00		А3		2005	0519									
	W:	ΑE,	AG,	AL,	AM,	AT,	ΑU,	ΑZ,	ΒA,	BB,	BG,	BR,	BW,	BY,	ΒZ,	CA,	CH,
		CN,	CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	EG,	ES,	FI,	GB,	GD,
		GE,	GH,	GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	ΚE,	KG,	KP,	KR,	ΚZ,	LC,
		LK,	LR,	LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MZ,	NA,	NI,
		NO,	NZ,	OM,	PG,	PH,	PL,	PT,	RO,	RU,	SC,	SD,	SE,	SG,	SK,	SL,	SY,
		ТJ,	TM,	TN,	TR,	TT,	TZ,	UA,	UG,	US,	UZ,	VC,	VN,	YU,	ZA,	ZM,	zw
	RW:	BW,	GH,	GM,	KE,	LS,	MW,	MZ,	NA,	SD,	SL,	SZ,	ΤZ,	UG,	ZM,	ZW,	AM,
		AZ,	BY,	KG,	ΚZ,	MD,	RU,	ТJ,	TM,	ΑT,	BE,	BG,	CH,	CY,	CZ,	DE,	DK,
		EE,	ES,	FI,	FR,	GB,	GR,	ΗU,	ΙĖ,	IT,	LU,	MC,	NL,	PL,	PT,	RO,	SE,
		SI,	SK,	TR,	BF,	ВJ,	CF,	CG,	CI,	CM,	GA,	GN,	GQ,	GW,	ML,	MR,	ΝE,
		SN,	TD,	TG													
CA	CA 2532917				AA		2005	0203		CA 2	004-	2532	917		2	0040	715
PRIORIT	RIORITY APPLN. INFO.:									DE 2	003-	1033	2790		A 2	0030	718
										WO 2	004-	EP79	24		W 2	0040	715
OTHER S	THER SOURCE(S):						142:	1980	91								

$$R^{1}$$
 $(R?)_{n}$

Title compds. [I; X, Y = N, CR4; n = 1-5; Ra = halo, cyano, alkyl, alkoxy, AB halogenalkyl, halogenalkoxy, alkenyl, alkenyloxy, COR5; R1, R2 = halo, cyano, alkyl, haloalkyl, alkenyl, alkynyl, halo, OR6, SR6, NR7R8, (haloand/or alkyl-substituted) cycloalkyl, cycloalkenyl; R3 = H, alkyl, halogenalkyl, cycloalkyl, optionally mono- or polysubstituted by alkyl and/or halo; R4 = H, halo, alkyl, haloalkyl, (alkyl and/or halo-substituted) cycloalkyl; R5 = H, OH, alkyl, alkoxy, haloalkyl, haloalkoxy, etc.; R6 = H, alkyl, haloalkyl, (substituted) phenylalkyl; R7, R8 = H, alkyl, alkenyl, alkadienyl, alkynyl, cycloalkyl, cycloalkenyl, Ph, phenylalkyl, naphthyl, heterocyclyl, etc.; R7R8N = atoms to form a 5-7 membered ring], were prepared Thus, Et 2,4,6-trifluoroacetate and Et 4-aminopyrimidine-5-carboxylate were heated together with NaOEt at 130° with distillation of EtOH to give 30% 6-(2,4,6trifluorophenyl)pyrido[2,3-d]pyrimidin-5,7-diol. This was heated with POC13 and PC15 at 130° for 8 h to give 95% 5,7-dichloro-6-(2,4,6trifluorophenyl)pyrido[2,3-d]pyrimidine. The latter at 250 ppm reduced incidence of Leptosphaeria nodorum infection on wheat to 3%, vs 80% for untreated controls.

IT 835878-70-1P

RL: AGR (Agricultural use); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyridopyridines and pyridopyrimidines as agrochem. fungicides)

RN 835878-70-1 HCAPLUS

CN 1,8-Naphthyridine, 2-chloro-3-(2,6-difluorophenyl)-4-(4-methyl-1-piperidinyl)- (9CI) (CA INDEX NAME)

L5 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:546506 HCAPLUS

DOCUMENT NUMBER: 141:89023

TITLE: A preparation of naphthyridine derivatives, useful as

plant fungicides

INVENTOR(S): Crowley, Patrick Jelf; Dobler, Markus; Mueller, Urs;

Williams, John

PATENT ASSIGNEE(S): Syngenta Limited, UK; Syngenta Participations A.-G.

SOURCE: PCT Int. Appl., 96 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PA	rent	NO.			KIN	D	DATE			APPL		ION I			D	ATE		
	2004				A2		2004		1	WO 2					2	0031	203	
WO	2004	0568	24		A3		2004	1014										
	W:	ΑE,	ΑG,	AL,	ΑM,	ΑT,	ΑU,	ΑZ,	BA,	BB,	BG,	BR,	BW,	BY,	ΒZ,	CA,	CH,	
		CN,	CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	EG,	ES,	FΙ,	GB,	GD,	
		GE,	GH,	GM,	HR,	ΗU,	ID,	IL,	IN,	IS,	JP,	ΚE,	KG,	ΚP,	KR,	ΚZ,	LC,	
		LK,	LR,	LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	ΜŻ,	NI,	NO,	
		NZ,	OM,	PG,	PH,	PL,	PT,	RO,	RU,	SC,	SD,	SE,	SG,	SK,	SL,	SY,	ТJ,	
		TM,	TN,	TR,	TT,	ΤZ,	UA,	ŪG,	US,	UZ,	VC,	VN,	YU,	ZA,	ZM,	ZW		
	RW:	BW,	GH,	GM,	ΚE,	LS,	MW,	MZ,	SD,	SL,	SZ,	ΤZ,	ŪG,	ZM,	ZW,	AM,	ΑZ,	
		BY,	KG,	ΚZ,	MD,	RU,	ТJ,	TM,	AT,	BE,	BG,	CH,	CY,	CZ,	DE,	DK,	EE,	
		ES,	FI,	FR,	GB,	GR,	ΗU,	IE,	IT,	LU,	MC,	NL,	PT,	RO,	SE,	SI,	SK,	
		TR,	BF,	ВJ,	CF,	CG,	CI,	CM,	GA,	GN,	GQ,	GW,	ML,	MR,	ΝE,	SN,	TD,	ΤG
CA	2507	670			AA		2004	0708		CA 2	003-	2507	670		2	0031	203	
ΑU	2003	2923	81		A1		2004	0714	. •	AU 2	003-	2923	81		2	0031	203	
ΕP	1585	746			A2		2005	1019		EP 2	003-	7679	58		2	0031	203	
	R:	AT,	BE,	CH,	DE,	DK,	ES,	FR,	GB,	GR,	ΙT,	LI,	LU,	NL,	SE,	MC,	PT,	
		ΙE,	SI,	LT,	LV,	FI,	RO,	MK,	CY,	AL,	TR,	BG,	CZ,	EE,	HU,	SK		

BR 2003017724 A 20051122 BR 2003-17724 20031203
PRIORITY APPLN. INFO.: GB 2002-30018 A 20021223
WO 2003-GB5248 W 20031203

OTHER SOURCE(S): MARPAT 141:89023

GI

- * STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY AVAILABLE VIA OFFLINE PRINT *
- ΔR The invention relates to a preparation of naphthyridine derivs. of formula I [wherein: one of W, X, Y and Z is N and the others are CH, C-halo, etc.; when X is CH , Z is N, R is NHNH2, R1 is Ph and R2 is C1, W and Y are both CCH3; one of R and R2 is NH2, N[alk(en/yn)yl]2, or aryl, etc., and the other is halo, alkyl, alkoxy, etc.; R1 is (hetero)aryl, morpholino, piperidino, or pyrrolidino], useful as plant fungicides. For instance, naphthyridine derivs. II (R3 = Cl; R4 = i-PrNH) and II (R3 = i-PrNH, R4 = Cl) were prepared via phenylacetylation of III (R5 = NH2) by 2,4,6-trifluorophenylacetyl chloride, intramol. heterocyclization of the obtained acetylaminonicotinate derivative III [R5 = 2,4,6-trifluoro-C6H4CH2C(O)NH], chlorination/aromatization of the obtained pyridotriazinedione derivative IV, and subsequent amination of the obtained dichloronaphthyridine derivative II (R3 = R4 = C1) by i-PrNH2 (example 1). For instance, naphthyridine derivative V gave greater than 60% control of disease (Plasmopara viticola).
- IT 714963-53-8P 714963-54-9P 714963-59-4P

RL: AGR (Agricultural use); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of fungicidal naphthyridine derivs. from nicotinic acid derivs.)

RN 714963-53-8 HCAPLUS

CN 1,8-Naphthyridin-4-amine, 2-chloro-N-(1-methylethyl)-3-(2,4,6-trifluorophenyl)- (9CI) (CA INDEX NAME)

$$F \longrightarrow F$$

RN 714963-54-9 HCAPLUS

CN 1,8-Naphthyridin-2-amine, 4-chloro-N-(1-methylethyl)-3-(2,4,6-trifluorophenyl)- (9CI) (CA INDEX NAME)

RN 714963-59-4 HCAPLUS
CN 1,8-Naphthyridine, 2-chloro-4-(4-morpholinyl)-3-(2,4,6-trifluorophenyl)(9CI) (CA INDEX NAME)

=> fil beilst

FILE 'BEILSTEIN' ENTERED AT 15:25:56 ON 23 MAR 2006 COPYRIGHT (c) 2006 Beilstein-Institut zur Foerderung der Chemischen Wissenschaften licensed to Beilstein GmbH and MDL Information Systems GmbH

FILE LAST UPDATED ON MARCH 15, 2006

FILE COVERS 1771 TO 2006.

*** FILE CONTAINS 9,516,393 SUBSTANCES ***

>>>PLEASE NOTE: Reaction Data and substance data are stored in separate documents and can not be searched together in one query. Reaction data for BEILSTEIN compounds may be displayed immediately with the display codes PRE (preparations) and REA (reactions). A substance answer set retrieved after the search for a chemical name, a compounds with available reaction information by combining with PRE/FA, REA/FA or more generally with RX/FA. The BEILSTEIN Registry Number (BRN) is the link between a BEILSTEIN compound and belonging reactions. For mo detailed reaction searches BRNs can be searched as reaction partner BRNs Reactant BRN (RX.RBRN) or Product BRN (RX.PBRN).<<<

>>> FOR SEARCHING PREPARATIONS SEE HELP PRE <<<

- * PLEASE NOTE THAT THERE ARE NO FORMATS FREE OF COST.
- * SET NOTICE FEATURE: THE COST ESTIMATES CALCULATED FOR SET NOTICE
- * ARE BASED ON THE HIGHEST PRICE CATEGORY. THEREFORE; THESE

- * ESTIMATES MAY NOT REFLECT THE ACTUAL COSTS.
- * FOR PRICE INFORMATION SEE HELP COST

NEW

- * PATENT NUMBERS (PN) AND BABS ACCESSION NUMBERS (BABSAN) CAN NOW BE SEARCHED, SELECTED AND TRANSFERRED.
- * NEW DISPLAY FORMATS ALLREF, ALLP AND BABSAN SHOW ALL REFERENCES, ALL PATENT REFERENCES, OR ALL BABS ACCESSION NUMBERS FOR A COMPOUND AT A GLANCE.

=> d que stat 111

STR L1 7

NODE ATTRIBUTES:

CONNECT IS E2 RC AT 1 CONNECT IS E2 RC AT 2 CONNECT IS E2 RC AT DEFAULT MLEVEL IS ATOM DEFAULT ECLEVEL IS LIMITED

10

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED NUMBER OF NODES IS 10

STEREO ATTRIBUTES: NONE L2STR



NODE ATTRIBUTES:

NSPEC IS RC AT3 CONNECT IS M2 RC AT 3 DEFAULT MLEVEL IS ATOM GGCAT IS PCY UNS AT DEFAULT ECLEVEL IS LIMITED ECOUNT IS E8 C E2 N AT

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED NUMBER OF NODES IS 4

STEREO ATTRIBUTES: NONE

3 SEA FILE=BEILSTEIN SSS FUL L1 AND L2 L10 &L11 O SEA FILE=BETLSTEIN ABB=ON PLU=ON L10/COM

=> fil marpat

FILE /MARPAT' ENTERED AT 15:26:05 ON 23 MAR 2006 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2006 American Chemical Society (ACS)

FILE CONTENT: 1961-PRESENT VOL 144 ISS 12 (20060317/ED)

SOME MARPAT RECORDS ARE DERIVED FROM INPI DATA FOR 1961-1987

MOST RECENT CITATIONS FOR PATENTS FROM MAJOR ISSUING AGENCIES (COVERAGE TO THESE DATES IS NOT COMPLETE):

2006035965 16 FEB 2006 DE 102004030305 12 JAN 2006 EΡ 1614691 11 JAN 2006 JΡ 2006008639 12 JAN 2006 2006012333 02 FEB 2006 WO 2415429 28 DEC 2005 GB 2873371 27 JAN 2006 FR 2267521 10 JAN 2006 RU CA 2472818 30 DEC 2005

Expanded G-group definition display now available.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

NODE ATTRIBUTES: CONNECT IS E2 RC AT

CONNECT IS E2 RC AT CONNECT IS E2 RC AT

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 10

STEREO ATTRIBUTES: NONE L2 STR

NODE ATTRIBUTES:

```
NSPEC IS RC AT 3
CONNECT IS M2 RC AT 3
DEFAULT MLEVEL IS ATOM
GGCAT IS PCY UNS AT 2
DEFAULT ECLEVEL IS LIMITED
ECOUNT IS E8 C E2 N AT
```


GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED NUMBER OF NODES IS 4

STEREO ATTRIBUTES: NONE

L4 4 SEA FILE=REGISTRY SSS FUL L1 AND L2 L5 2 SEA FILE=HCAPLUS ABB=ON PLU=ON L4 L13 550 SEA FILE=MARPAT SSS FUL L1

L17 STR



NODE ATTRIBUTES:

NSPEC IS RC AΤ 11 CONNECT IS E2 RC AT 1 CONNECT IS E2 RC AT 2 CONNECT IS E2 RC AT 6 CONNECT IS M2 RC AT 11 RC AT CONNECT IS E1 12 DEFAULT MLEVEL IS ATOM DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

", Ļ19

RING(S) ARE ISOLATED OR EMBEDDED NUMBER OF NODES IS 13

STEREO ATTRIBUTES: NONE

L18 12 SEA FILE=MARPAT SUB=L13 SSS FUL L17

10 SEA FILE=MARPAT ABB=ON PLU=ON L18 NOT L5

=> d 119 ibib abs qhit 1-10

L19 ANSWER 1 OF 10 MARPAT COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 140:199210 MARPAT

TITLE: Preparation of aminocyclohexene-substituted quinolines

and their azaisosteric analogues with antibacterial

activity

INVENTOR(S): Davies, David Thomas; Elder, John Stephen; Forrest,

Andrew Keith; Jarvest, Richard Lewis; Pearson, Neil

David; Sheppard, Robert John

PATENT ASSIGNEE(S): Glaxo Group Limited, UK

SOURCE: PCT Int. Appl., 60 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PA	TENT	NO.		KI	ND					PPLI	_			DATE			
	2004 2004					2004	0219							2003	0723		
		AE,	AG,	AL,	AM,	AT,	AU,							BZ,			
		GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	KE,	KG,	KP,	KR,	GB, KZ,	LC,	LK,	LR,
				•		•	•				•	•		NI, SY,		•	•
	₽W•					UG,		•	•	•	•			ZW ZW,	ΔM	Δ7	RV
	100.	KG,	ΚZ,	MD,	RU,	ТJ,	TM,	AT,	BE,	BG,	CH,	CY,	CZ,	DE,	DK,	EE,	ES,
		•	•	•	•	•	•	•	•	•	•	•	•	SE, NE,	•	•	•
	2003 1539																
	R:			•		•								NL, EE,	•	•	PT,
	2005	5381	25	T	2	2005	1215		J.	P 20	04-5	2677	3	2003	0723		
PRIORIT	2006 Y APP				L	2006	0223		G:	В 20	02-1	7294		2002	0725		
GI									W	0 20	03-E	P815	3	2003	0723		

AB (CH₂)
$$n$$
 R^2
 Z^1
 Z^5
 Z^4

AB Title compds. I [one of Z1-5 = N, one = CR1a and the remainder are CH, etc.; R1-1a = H, OH, (un)substituted alkoxy, etc.; R2 = H, (un)substituted-alkyl, -alkenyl; R3 = OH, alkoxy, alkenyloxy, etc.; R4 = alkyl, hydroxyalkyl, alkoxyalkyl, heterocycle, etc.; n = 0-1; AB = amido, carboxamido, acyl, etc.] and there pharmaceutically acceptable salts are prepd and disclosed as antibacterial agents. For instance, 4-amino-1-hydroxycyclohex-2-enecarboxylic acid N-(6-methoxy[1,5]naphthyridin-4-yl)amide (preparation given) is reductively

Ι

alkylated with 3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-carboxaldehyde to give II. II possessed an MIC of \leq 2 $\mu g/mL$ against S epidermidis CL7, S. aureus WCUH29, S. pneumoniae 1629, S. pyogenes CN10, H. influenzae ATCC 49247, E. faecalis 2, M. catarrhalis Ravasio, and E. coli 7623.

MSTR 1

G1---G2

G1 = 111

G3 G3 G3 G3 G3 G3

G2 = imidazolyl G3 = F / piperidino

Patent location: claim 1

Note: also incorporates claims 13 and 14
Note: additional derivatization also claimed

Note: substitution is restricted

L19 ANSWER 2 OF 10 MARPAT COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 139:337959 MARPAT

TITLE: Preparation of nitrogen-containing bicyclic

heterocycles for use as antibacterials

INVENTOR(S): Brooks, Gerald; Davies, David Thomas; Jones, Graham

Elgin; Markwell, Roger Edward; Pearson, Neil David

PATENT ASSIGNEE(S): Smithkline Beecham P.L.C., UK

SOURCE: PCT Int. Appl., 163 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PA	rent	NO.		KI	ND	DATE			A.	PPLI	CATI	ои ис	ο.	DATE			
									-								
WO	2003	0870	98	Α	1	2003	1023		W	20	02-E	P570	8	2002	0524		
	W:	ΑE,	ΑG,	AL,	AM,	AT,	ΑU,	ΑZ,	BA,	BB,	BG,	BR,	BY,	ΒZ,	CA,	CH,	CN,
		CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	ES,	FΙ,	GB,	GD,	GE,	GH,
		GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	ΚE,	KG,	ΚP,	KR,	ΚZ,	LC,	LK,	LR,
		LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MZ,	NO,	ΝZ,	OM,	PH,
		PL,	PT,	RO,	RU,	SD,	SE,	SG,	SI,	SK,	SL,	ТJ,	TM,	TN,	TR,	TT,	ΤZ,
		UA,	UG,	US,	UZ,	VN,	YU,	ZA,	ZM,	zw							
	RW:	GH,	GM,	ΚE,	LS,	MW,	MZ,	SD,	SL,	SZ,	ΤZ,	UG,	ZM,	ZW,	AM,	ΑZ,	BY,
		KG,	ΚZ,	MD,	RU,	ТJ,	TM,	AT,	BE,	CH,	CY,	DE,	DK,	ES,	FΙ,	FR,	GB,
		GR,	ΙE,	IT,	LU,	MC,	NL,	PT,	SE,	TR,	BF,	ВJ,	CF,	CG,	CI,	CM,	GA,
		GN,	GQ,	GW,	ML,	MR,	ΝE,	SN,	TD,	ΤG							
CA	2448	525		A	A	2003	1023		C.	A 20	02-2	4485	25	2002	0524		

AU	20023	6769	97	A.	Ĺ	2003	1027		ΑŪ	J 20	02-3	6769°	7	2002	0524		
EP	13994	43		A.	L	2004	0324		Εl	P 20	02-8	07202	2	2002	0524		
	R:	ΑT,	BE,	CH,		DK,		•		•	•	LI,	LŲ,	NL,	SE,	MC,	PT,
		ΙE,	SI,	LT,	LV,	FΙ,	RO,	MK,	CY,	AL,	TR						
BR	20020	1001	L 6	Α		2004	0615		BI	R 20	02-1	0016		2002	0524		
CN	15352	72		Α		2004	1006		Cì	N 20	02-8	14668	8	2002	0524		
JP	20055	1998	31	T	2	2005	0707		JI	P 20	03-5	84054	4	2002	0524		
ZA	20030	0869	96	Α		2004	0521		\mathbf{z}	A 20	03-8	696		2003	1107		
US	20041	7162	20	A.	L	2004	0902		US	S 20	04-4	7815	4	2004	0406		
PRIORIT	Y APPL	N.]	NFO	. :					GI	3 20	01-1	2834		2001	0525		
									W	20	02-E	P5708	8	2002	0524		
GI																	

AB (CH₂)
$$n$$

AB (CH₂) n

NR²R4

R1

Z2

Z3

N

N

N

NR²R4

Naphthyridines I [one of 21-25 = N, one = (un)substituted Ch, the others = AΒ CH; one of Z1-Z5 = (un) substituted Ch, the others = CH; R1 = H, OH, halogen, (un) substituted alkoxy, alkyl, alkylthio, CF3, NO2, N3, acyl, acyloxy, acylthio, alkylsulfonyl, alkylsulfinyl, arylsulfonyl, arylsulfinyl, amino; R2 = H, (un)substituted alkyl, alkenyl; R3 = H, CO2H, alkoxycarbonyl, (un) substituted alkyl, CONH2, CN, tetrazolyl, 2-oxooxazolidinyl, 3-hydroxy-3-cyclobutene-1,2-dion-4-yl,2,4thiazolidinedion-5-yl, 1,2,4-triazol-5-yl, 5-oxo-1,2,4-oxadiazol-3-yl; R4 = (un)substituted alkyl, heterocyclic; R5, R6 = H; R5R6 = bond; AB = (un) substituted CONH, NHCO, COCH2, CH2CO, OCH2, CH2O, NHCH2, CH2NH, NHSO2, CH2SO2, CH2CH2; n = 0, 1] were prepared for use as bactericides. Thus, 2,1,3-benzothiadiazole-5-carboxylic acid was reduced to the alc., mesylated, and treated with the amine fragment, prepared from 5-amino-2-methoxypyridine in 5 steps, to give the naphthyridine II, which had IC50 against Staphylococcus aureus Oxford, several S. pneumoniae strains, and Escherichia coli strains of $\leq 4 \, \mu \text{g/mL}$.

ΙI

MSTR 1

G1—G2

G1 = 44

G2 = imidazolyl

Note: also incorporates claims 13, 14, and 15

Note: substitution is restricted

Note: additional ring formation also claimed

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 3 OF 10 MARPAT COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 138:153541 MARPAT

TITLE: Preparation of N-(1,5-naphthyridin-4-yl)piperidine-4-

carboxamide derivatives as antibacterial agents

INVENTOR(S): Davies, David Thomas; Jones, Graham Elgin; Markwell,

Roger Edward; Pearson, Neil David

PATENT ASSIGNEE(S): Smithkline Beecham PLC, UK

SOURCE: PCT Int. Appl., 97 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PA	rent :	NO.		KI	ND	DATE			A		CATIO			DATE			
	2003								W		02-E			2002	0725		
WO	2003	0101	38	A.	3	2003	1204										
	W:	ΑE,	AG,	AL,	AM,	ΑT,	ΑU,	ΑZ,	BA,	BB,	BG,	BR,	BY,	ΒZ,	CA,	CH,	CN,
		CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	ES,	FI,	GB,	GD,	GE,	GH,
														KZ,			
			-						•					NO,			•
		-	-			-	•		-	•				TN,	•	•	
						VN,	•	•		•	,	,	,	,	,	,	,
	RW:										Т2.	UG.	7.M.	ZW,	AM.	A7.	BY.
														DE,			
						-			-			•	-	TR,			
					-	GN,			-				-	-	טני,	БО,	CI,
חים	1 4 1 0		•			•		•	•						7775		
EP	1419													2002			
	R:						•				•			NL,		MC,	PT,
		ΙE,	SI,	LT,	LV,	FI,	RO,	MK,	CY,	AL,	TR,	BG,	CZ,	EE,	SK		
JP	2005	5047	47	T	2	2005	0217		J:	P 20	03-5	1549	7	2002	0725		
US	2004	1987	56	Α	1	2004	1007		U	S 20	04-4	8456	3	2004	0524		
PRIORIT	Y APP	LN.	INFO	. :					G	B 20	01-1	8238		2001	0726		
				• •										2002			
GI									***	20	·	. 001	_	2002	0,23		

Ι

AB The title piperidine derivs. [I; one of Z1-Z5 is N, one is CR1a and the remainder are CH, or one or two of Z1-Z5 are independently CR1 a and the remainder are CH; R1, R1a = H, HO, C1-6 alkoxy optionally substituted by (un) substituted C1-6 alkoxy, amino, piperidyl, guanidino or amidino, C1-6 alkoxy-C1-6 alkyl, halo, C1-6 alkyl, C1-6 alkylthio, CF3, CF30, etc.; R3 = CO2H, C1-6 alkoxycarbonyl, (un) substituted CONH2, cyano, tetrazolyl, (un) substituted 2-oxooxazolidinyl, 3-hydroxy-3-cyclobutene-1,2-dione-4-yl, 2,4-thiazolidinedione-5-yl, tetrazol-5-ylaminocarbonyl, (un)substituted 1,2,4-triazol-5-yl, 5-oxo-1,2,4-oxadiazol-3-yl, (un)substituted C1-4 alkyl or ethenyl, halogen, C1-6 alkylthio, CF3, C1-6 alkoxycarbonyl, C1-6 alkylcarbonyl, C2-6 alkenyloxycarbonyl, C2-6 alkenylcarbonyl, (un) substituted OH or NH2, etc.; R31 is in the 2- or 3-position and is hydrogen or a group listed above for R3, provided that R31 in the 2-position is not optionally substituted hydroxy, amino, trifluoromethyl or halogen; R4 = CH2R51, U-V-R52 (wherein R51 = C4-8 alkyl, hydroxy-C4-8alkyl, C1-4 alkoxy-C4-8 alkyl, etc.; U = CO, SO2, CH2 and V =(un) substituted CH2; or U = CH2 and V = CO, (un) substituted C(:NOH), SO2; R52 = (un) substituted bicyclic carbocyclic or heterocyclic ring); n = 0,1; AB = (un)substituted NHCO, CONH, COCH2, CH2CO, OCH2, CH2O, NHCH2, CH2NH, NHSO2, CH2 SO2, CH2CH2] and pharmaceutically acceptable derivs. thereof are prepared These compds. are useful in methods of treatment of bacterial infections in mammals, particularly man. Thus, 0.10 g 4-(6-methoxy-[1,5]naphthyridin-4-ylcarbamoyl)-4-methylpiperidine and 0.095 g 2-(3-0xo-3,4-dihydro-2H-benzo[1,4]thiazin-6-yl)ethyl methanesulfonate were stirred with 138 mg K2CO3 in 2 mL DMF at room temperature for 3 days to give 4-methyl-1-[2-(3-oxo-3,4-dihydro-2H-benzo[1,4]thiazin-6yl)ethyl]piperidine-4-carboxylic acid (6-methoxy-[1,5]naphthyridin-4yl)amide (II). II oxalate showed min. inhibitory concentration of ≤ 4 μg/mL against Staphylococcus aureus Oxford, S. aureus WCUH29, S. pneumoniae 1629, S. pneumoniae N1387, S. pneumoniae ERY 2, Enterococcus faecalis I, E. faecalis 7, Haemophilus influenzae Q1, H. influenzae NEMC1, Moraxella catarrhalis 1502, and Escherichia coli 7623.

MSTR 1

G1 = F / piperidino G6 = 42-1 39-3 34-66 35-67

```
42
G1
N 39
34
N 35
```

G8 = imidazolyl

Patent location:

Note: substitution is restricted

Note: additional ring formation also claimed

claim 1

Note: also incorporates claim 13

Note: and precursors

Note: or pharmaceutically acceptable derivatives

L19 ANSWER 4 OF 10 MARPAT COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 138:14011 MARPAT

TITLE: Preparation of bicyclic nitrogen-containing

heterocyclic derivatives for use as antibacterials INVENTOR(S): Dartois, Catherine Genevieve Yvette; Markwell, Roger

Edward; Madler, Guy Marguerite Marie Gerard; Pearson,

Neil David

PATENT ASSIGNEE(S): Smithkline Beecham P.L.C., UK

SOURCE: PCT Int. Appl., 71 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

	PA	PENT	NO.		KI	ND	DATE			A	PPLI	CATI	ои ис	э.	DATE				
	WO	2002	 0969	07	A	1	2002	1205		W	20	02-E	P570	9	2002	0524			
		W:	ΑE,	AG,	AL,	AM,	AT,	ΑU,	AZ,	BA,	BB,	BG,	BR,	BY,	ΒZ,	CA,	CH,	CN,	
			CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	ES,	FI,	GB,	GD,	GE,	GH,	
			GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	ΚE,	KG,	ΚP,	KR,	ΚZ,	LC,	LK,	LR,	
			LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MZ,	NO,	ΝZ,	OM,	PH,	
			PL,	PT,	RO,	RU,	SD,	SE,	SG,	SI,	SK,	SL,	ТJ,	TM,	TR,	TT,	ΤZ,	UA,	
			UG,	US,	UZ,	VN,	YU,	ZA,	ZM,	ZW,	AM,	ΑZ,	BY,	KG,	ΚZ,	MD,	RU,	ТJ,	TM
		RW:	GH,	GM,	KE,	LS,	MW,	MZ,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,	AT,	BE,	CH,	
			CY,	DE,	DK,	ES,	FI,	FR,	GB,	GR,	ΙE,	IT,	LU,	MC,	NL,	PT,	SE,	TR,	
			BF,	ВJ,	CF,	CG,	CI,	CM,	GA,	GN,	GQ,	G₩,	ML,	MR,	ΝE,	SN,	TD,	ΤG	
	ΕP	1392	686		Α	1	2004	0303		E	P 20	02-7	7402	2	2002	0524			
		R:	ΑT,	BE,	CH,	DE,	DK,	ES,	FR,	GB,	GR,	IT,	LI,	LU,	NL,	SE,	MC,	PT,	
			ΙE,	SI,	LT,	LV,	FI,	RO,	MK,	CY,	AL,	TR							
	JP	2004	5347	80	T	2	2004	1118		J	P 20	03-5	8000	6	2002	0524			
	US	2004	1987	55	Α	1	2004	1007		U	S 20	04-4	7790	0	2004	0524			
PRIO	RIT	Y APP	LN.	INFO	. :					G	B 20	01-1	2836		2001	0525			
										W	0 20	02-E	P570	9	2002	0524			
GI																			

AB Piperidine derivs. and pharmaceutically acceptable derivs. [I; wherein one of Z1, Z2, Z3, Z4, Z5 = N, one is CR2 (wherein R2 = H, OH, (C1-C6)alkoxy, etc.) and the remainder are CH, or one of Z1, Z2, Z3, Z4, Z5 = CR2 and the remainder are CH; R3 = H, carboxy, (C1-C6)alkoxycarbonyl, aminocarbonyl, cyano, tetrazolyl, etc.; R4 = U-V-R5, wherein U-V = (CH2)2, CH2CH(OH), CH2CO, and R5 is a (substituted) bicyclic carbocyclic or heterocyclic ring system] were prepared For example, II was prepared by a multistep synthetic procedure. The prepared compds. are useful in the treatment of bacterial infections in mammals, particularly man. For example, compound II had MIC values $\leq 4~\mu g/mL$ against S. aureus Oxford.

MSTR 1

G8 = imidazolyl

Patent location: claim 1

Note: substitution is restricted

Note: additional ring formation also claimed

Note: also incorporates claim 13

Note: and precursors

Note: or pharmaceutically acceptable derivatives

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 5 OF 10 MARPAT COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 137:125092 MARPAT

TITLE: Preparation of 4-piperidinylquinolines and nitrogenated analogs as antibacterial agents

INVENTOR(S): Davies, David Thomas; Jones, Graham Elgin; Markwell,

Roger Edward; Miller, William; Pearson, Neil David PATENT ASSIGNEE(S): Smithkline Beecham P.L.C., UK

SOURCE: PCT Int. Appl., 94 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

```
KIND DATE
                                   APPLICATION NO. DATE
    PATENT NO.
    -----
                   ----
                                       -----
                          20020725 WO 2002-EP587 20020122
    WO 2002056882
                   A1
        W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
            CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
            GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
            LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
            PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA,
            UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
        RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
           CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
            BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
                                      EP 2002-702296 20020122
    EP 1359908
                    A1 20031112
           AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
                                        JP 2002-557390
                                                        20020122
    JP 2004520360
                   Т2
                          20040708
                                                        20040126
                                        US 2004-466394
    US 2004138219
                     A1
                          20040715
                                        GB 2001-1577
                                                        20010122
PRIORITY APPLN. INFO.:
                                        WO 2002-EP587
                                                        20020122
GΙ
```

Ι

Title compds. I [wherein one of 21-25 = N, one = CR1a, and the remainder = AB CH; or one of Z1-Z5 = CR1a and the remainder = CH; R1 and R1a = independently H, OH, or (un) substituted alkoxy; R2 = H or (un) substituted alkyl or alkenyl; R3 = H, carboxy, alkoxycarbonyl, alkenyloxycarbonyl, or (un) substituted aminocarbonyl, alkyl, or ethenyl; R4 = UR5; U = CO, SO2, or CH2; R5 = (un)substituted bicyclic carbocyclic or heterocyclic ring; n = 0 and AB = (un)substituted NHCO, COCH2, CH2CO, NHSO2, CH2SO2, or CH2CH2; or n = 0 and AB = NHCO, COCH2, CH2CO, NHSO2, CONH, CH2CH2, OCH2, or NHCH2; with provisos; and pharmaceutically derivs. thereof] were prepared for the treatment of gram pos. and gram neg. bacterial infections in mammals, particularly in man. For example, quininone was treated with t-BuOK in t-BuOH and H2O to give 6-methoxyquinoline-4-carboxylic acid (46%), which was converted to (R)-2-(6-methoxyquinoline-4-yl)oxirane over several steps. Reaction with LiClO4 in anhydrous DMF, 4-tertbutoxycarbonylaminopiperidine HCl, and K2CO3 with heating to 90° for 26 h afforded 4-tert-butoxycarbonylamino-1-[2-(R)-hydroxy-2-(6-methoxyquinoline-4-yl)ethyl]piperidine. Deprotection, condensation with 2,3-dihydrobenzo[1,4]dioxine-6-carboxaldehyde, and conversion to the salt gave II-2HO2CCO2H. The latter demonstrated antibacterial activity with MIC \leq 0.125 μM against one or more of the gram pos. and gram neg. bacteria tested.

MSTR 1

42 G1 N N 35

G8 = imidazolyl

Patent location:

Note: substitution is restricted

Note: additional ring formation also claimed

claim 1

Note: also incorporates claim 16

Note: and precursors

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 6 OF 10 MARPAT COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 137:63259 MARPAT

TITLE: Preparation of piperazines as antibacterials.

INVENTOR(S): Dartois, Catherine Genevieve Yvette; Markwell, Roger

Edward; Morvan, Marcel; Nadler, Guy Marguerite Marie

Gerard; Pearson, Neil David

PATENT ASSIGNEE(S): Smithkline Beecham P.L.C., UK

SOURCE: PCT Int. Appl., 55 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


	KIND DATE		DATE
	A1 20020627 C1 20020725	WO 2001-GB5653	20011219
W: AE, AG, CO, CR, GM, HR, LS, LT, PL, PT, UG, US,	AL, AM, AT, AU, AZ, CU, CZ, DE, DK, DM, HU, ID, IL, IN, IS, LU, LV, MA, MD, MG, RO, RU, SD, SE, SG, UZ, VN, YU, ZA, ZM, KE, LS, MW, MZ, SD,	DZ, EC, EE, ES, FI, JP, KE, KG, KP, KR, MK, MN, MW, MX, MZ, SI, SK, SL, TJ, TM, ZW, AM, AZ, BY, KG,	GB, GD, GE, GH, KZ, LC, LK, LR, NO, NZ, OM, PH, TR, TT, TZ, UA, KZ, MD, RU, TJ, TM
CY, DE, BF, BJ, AU 2002022287	DK, ES, FI, FR, GB, CF, CG, CI, CM, GA, A5 20020701	GR, IE, IT, LU, MC, GN, GQ, GW, ML, MR, AU 2002-22287	NL, PT, SE, TR, NE, SN, TD, TG 20011219
R: AT, BE, IE, SI,	A1 20030917 CH, DE, DK, ES, FR, LT, LV, FI, RO, MK, T2 20040624	GB, GR, IT, LI, LU, CY, AL, TR	
	A1 20040422	US 2003-450884 GB 2000-31088	20031113 20001220 20011219

Ι

AB Title compds. [I; 1 of Z1-Z5 = N, 1 = CR1a, the remainder = CH, 1 of Z1-Z5= CRla and the remainder = CH; Rl, Rla = H, OH, (substituted) alkoxy, alkoxyalkyl, amino, amidino, etc.; R3 = H, CO2H, alkoxycarbonyl, cyano, tetrazolyl, (substituted) aminocarbonyl, etc.; R4 = UVR5; R5 = (substituted) bicyclic carbocyclyl, heterocyclyl; U = CO, SO2, CH2, and V= CR17R18; or U = CH2 and V = CO, SO2; R17, R18 = H, (substituted) OH, amino; n = 0, 1; AB = NR11CO, COCR8R9, NHR11SO2, etc.; R8, R9 = H, alkoxy, alkylthio, halo, CF3, N3, alkyl, alkenyl, alkoxycarbonyl, alkylcarbonyl, R11 = H, CF3, alkyl, alkenyl, alkoxycarbonyl, alkylcarbonyl, (substituted) aminocarbonyl; with provisos], were prepared Thus, (R)-1-[(6methoxyquinolin-4-yl)-2-piperazin-1-yl]ethanol (preparation given), K2CO3, and 2-(2-bromoethyl)isoindole-1,3-dione were stirred 3 h in DMF to give 2-[2-[4-[(R)-2-OH-2-(6-methoxyquinolin-4-yl)]]yl]ethyl]isoindole-1,3-dione. I showed min. inhibitory concns. of ≤0.25 µg/mL against S. aureus Oxford, H. influenzae Q1, E. faecalis 7, etc.

MSTR 1

G1 = F / piperidino G6 = 42-1 39-3 34-66 35-67



G8 = imidazolyl

Patent location: claim 1

Note: substitution is restricted

Note: additional ring formation also claimed

Note: also incorporates claim 12

Note: and precursors

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 7 OF 10 MARPAT COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 137:47229 MARPAT

TITLE: Preparation of piperazinylalkylquinolines as

antibacterial agents.

INVENTOR(S): Markwell, Roger Edward; Pearson, Neil David;

Smethurst, Christian

PATENT ASSIGNEE(S): Smithkline Beecham PLC, UK

SOURCE: PCT Int. Appl., 51 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PA	TENT	NO.		KI	ND	DATE			A	PPLI	CATI	ои ис	0.	DATE				
WO	2002	0500	40	A	1	2002	0627		W	20	01-G	B566:	1	2001	1219			
	W:	ΑE,	AG,	AL,	AM,	AT,	ΑU,	ΑZ,	BA,	BB,	BG,	BR,	BY,	ΒZ,	CA,	CH,	CN,	
		CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	ES,	FI,	GB,	GD,	GE,	GH,	
		GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	ΚE,	KG,	ΚP,	KR,	ΚZ,	LC,	LK,	LR,	
		LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MZ,	NO,	ΝZ,	OM,	PH,	
		PL,	PT,	RO,	RU,	SD,	SE,	SG,	SI,	SK,	SL,	ТJ,	TM,	TR,	TT,	TZ,	UA,	
		UG,	US,	UZ,	VN,	YU,	ZA,	ZM,	ZW,	AM,	AZ,	ΒY,	KG,	ΚZ,	MD,	RU,	ТJ,	TM
	RW:	GH,	GM,	ΚE,	LS,	MW,	ΜZ,	SD,	SL,	SZ,	ΤZ,	UG,	ZM,	ZW,	AT,	BE,	CH,	
		CY,	DE,	DK,	ES,	FI,	FR,	GB,	GR,	ΙE,	IT,	LU,	MC,	NL,	PT,	SE,	TR,	
		BF,	ВJ,	CF,	CG,	CI,	CM,	GA,	GN,	GQ,	GW,	ML,	MR,	ΝE,	SN,	TD,	TG	
AU	2002	0162	14	Α	5	2002	0701		A	U 20	02-1	6214		2001	1219			
EΡ	1343	765		Α	1	2003	0917		E.	P 20	01-2	7136	1	2001	1219			
	R:	AT,	BE,	CH,	DE,	DK,	ES,	FR,	GB,	GR,	IT,	LI,	LU,	NL,	SE,	MC,	PT,	
		ΙE,	SI,	LT,	LV,	FI,	RO,	MK,	CY,	AL,	TR							
JP	2004	5186	60	T	2	2004	0624		J	P 20	02-5	5153	7	2001	1219			
US	2004	0776	56	Α	1	2004	0422		U	S 20	03-4	5089	2	2003	1113			
PRIORIT	Y APP	LN.	INFO	.:					G:	B 20	00-3	1086		2000	1220			
									W	0 20	01-G	B566	1	2001	1219			
GI																		

II

Ι

Title compds. [I; 1 of Z1-Z5 = H, 1 = CR1a, the rest = CH, or 1 of Z1-Z5 =ΑB CR1a, the remainder = CH; R1, R1a = H, OH, (substituted) alkoxy, etc.; R3 = H, CO2H, alkoxycarbonyl, aminocarbonyl, etc.; R4 = VX1X2X3X4; V = CH2, CO, SO2; X1 = CR14R15; X2 = NR13, O, SO2, CR14R15; X3 = NR13, O, CR14R15; R14, R15 = H, alkoxy, alkylthio, CF3, cyano, alkyl, alkenyl, alkoxycarbonyl, alkylcarbonyl, etc.; R14R15 = 0; R13 = H, CF3, alkyl, alkenyl, alkoxycarbonyl, alkylcarbonyl, aminocarbonyl; X4 = Ph, (substituted) heteroaryl, etc.; n = 0, 1; AB = NR11CO, NR11SO2, COR8R9, etc.; R8, R9 = H, alkoxy, alkylthio, halo, CF3, N3, alkyl, alkenyl, alkoxycarbonyl, etc.; R11 = H, CF3, alkyl, alkenyl, alkoxycarbonyl, alkylcarbonyl, aminocarbonyl, etc.; with provisos], were prepared Thus, (R)-1-(6-methoxyquinolin-4-yl)-2-[4-(S)-1-oxiranylmethylpiperazin-1yl]ethanol and 3,5-difluoroaniline were refluxed 8 h in EtOH to give 12% title compound (II). Several I had min. inhibitory concns. of <8 µg/mL against S aureus Oxford, pneumoniae 1629, etc.

MSTR 1

 $G1 = 33-1 \ 30-4 \ 25-74 \ 26-75$

G3 = F / piperidino

G5 = imidazolyl

Patent location: claim 1

Note: substitution is restricted

Note: or pharmaceutically acceptable derivatives additional substitution and ring formation also

claimed

Note: also incorporates claim 12

Note: or precursors

REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 8 OF 10 MARPAT COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 136:279352 MARPAT

TITLE: Preparation and biol. activity of

aminopiperidine-containing

quinolines as antibacterial agents especially for use

in humans

INVENTOR(S): Davies, David Thomas; Markwell, Roger Edward; Pearson,

Neil David

PATENT ASSIGNEE(S): Smithkline Beecham P.L.C., UK

PCT Int. Appl., 90 pp. SOURCE:

CODEN: PIXXD2

DOCUMENT TYPE:

Patent English

LANGUAGE:

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PA	TENT	NO.		KI	ND	DATE			A	PPLI	CATI	ои ис	ο.	DATE			
WO	2002	0246	84	A	1	2002	0328		W	20	01-E	P109	76	2001	0919		
	W:	ΑE,	AG,	AL,	AM,	ΑT,	ΑU,	AZ,	BA,	BB,	BG,	BR,	BY,	ΒZ,	CA,	CH,	CN,
		CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	ES,	FI,	GB,	GD,	GE,	GH,
		GM,	HR,	ΗU,	ID,	IL,	IN,	IS,	JP,	ΚE,	KG,	ΚP,	KR,	ΚZ,	LC,	LK,	LR,
		LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	ΜZ,	NO,	NZ,	PH,	PL,
		PT,	RO,	RU,	SD,	SE,	SG,	SI,	SK,	SL,	ТJ,	TM,	TR,	TT,	ΤZ,	UA,	UG,
		US,	UZ,	VN,	YU,	ZA,	ZW,	AM,	ΑZ,	BY,	KG,	ΚZ,	MD,	RU,	TJ,	TM	
	RW:	GH,	GM,	ΚE,	LS,	MW,	ΜZ,	SD,	SL,	SZ,	ΤZ,	UG,	ZW,	ΑT,	BE,	CH,	CY,
		DE,	DK,	ES,	FI,	FR,	GB,	GR,	ΙE,	ΙΤ,	LU,	MC,	NL,	PT,	SE,	TR,	BF,
		ВJ,	CF,	CG,	CI,	CM,	GA,	GN,	GQ,	GW,	ML,	MR,	NE,	SN,	TD,	TG	
AU	2002	0181	92	Α	5	2002	0402		A	U 20	02-1	8192		2001	0919		
EP	1320	529		Α	1	2003	0625		E	P 20	01-9	8525	3	2001	0919		
	R:	ΑT,	BE,	CH,	DE,	DK,	ES,	FR,	GB,	GR,	IT,	LI,	LU,	NL,	SE,	MC,	PT,
		ΙE,	SI,	LT,	LV,	FI,	RO,	MK,	CY,	AL,	TR						
	2004													2001	0919		
US	US 2004053928 A1 2004031									S 20	03-3	8091	5	2003	0904		
PRIORIT	Y APP	LN.	INFO	.:					G:	B 20	00-2	3211		2000	0921		
									G:	B 20	01-1	628		2001	0122		
									M	0 20	01-E	P109	76	2001	0919		

Title compds. I [one of Z1-Z5 = N, one = CR1a and the remainder = CH; or AΒ one or two of Z1-Z5 = independently CR1a and the remainder = CH; R1a, R1 = H, OH, (substituted) alkoxy, halo, alkylthio, CF3, NO2, N3, acyl, acyloxy, acylthio, etc.; R2 = H, (substituted) alkyl, (substituted) alkenyl; R3 = H, CO2H, alkoxycarbonyl, (substituted) aminocarbonyl, alkyl, ethenyl, etc.; R4 = X1X2X3X4; X1 = CH2, CO, SO2; X2 = CR14R15; X3 = O, S, NR13, CR14R15; R14, R15 = H, halo, alkoxy, alkylthio, CF3, cyano, CO2H, formyl, NO2, amino, OH, alkoxy, aminocarbonyl, alkylsulfonyl, etc.; R14R15 = :0;

R13 = H, CF3, alkyl, alkenyl, alkoxycarbonyl, alkylcarbonyl, aminocarbonyl, etc.; X4 = Ph, halo, CO2H, alkyl, alkoxy, alkenyl, alkoxycarbonyl, formyl, alkylcarbonyl, alkylcarbonyloxy, NO2, cyano, amino, C- or N-linked 5- or 6-membered, substituted heterocycle containing \leq 4 heteroatoms, etc; n = 0, 1; A = NR11, O, CR6R7; B = NR11, O, SO2, CR8R9; R6-R9 = H, alkoxy, alkylthio, halo, CF3, OH, N3, NH2, alkyl, alkenyl, alkoxycarbonyl, alkylcarbonyl, aminocarbonyl, etc.; R11 = H, CF3, alkyl, alkenyl, alkoxycarbonyl, alkylcarbonyl, (substituted) aminocarbonyl], with provisos, were prepared For example, methoxyquinoline derivative II·dioxalate was prepared in several steps from starting materials of (R)-2-(6-methoxyquinolin-4-yl)oxirane, 1,4-dioxa-8-azaspiro-[4,5]-decane, N-Boc-glycine N-hydroxysuccinimide ester and PhNH2. II·dioxalate showed min. inhibitory concentration (MIC) of \leq 0.25 $\mu g/mL$ against various strains of bacteria.

MSTR 1

G1 = 46-3 51-5

G3 = piperidino / F G12 = 178-4 179-6

178 179

G13 = NH (opt. substd.)

Patent location: claim

Note: or pharmaceutically acceptable derivatives

Note: substitution is restricted

MSTR 2

G2—G1—G12

G1 = 46-351-5

G13 = NH (opt. substd.)

Patent location: claim 13

MSTR 4

$$G1 = 46-3 51-5$$

G3 = piperidino / F G12 = 178-4 179-6

178 179

G13 = NH (opt. substd.)

Patent location: claim 14

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 9 OF 10 MARPAT COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 136:151082 MARPAT

TITLE: Preparation of aminopiperidine quinolines and their azaisosteric analogs having antibacterial activity

INVENTOR(S): Davies, David Thomas; Jones, Graham Elgin; Lightfoot,

Andrew P.; Markwell, Roger Edward; Pearson, Neil David

Smithkline Beecham P.L.C., UK PCT Int. Appl., 80 pp. PATENT ASSIGNEE(S):

SOURCE:

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT: 1

PA	rent	NO.		KI	ND.	DATE			Al	PLI	CATI	ON NC	o.	DATE			
WO	2002	0082	24	А	1	2002	0131		W	20	01-E	P860	4	2001	0725		
	W:	ΑE,	AG,	AL,	AM,	ΑT,	ΑU,	ΑZ,	BA,	BB,	BG,	BR,	BY,	BZ,	CA,	CH,	CN,
		CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EE,	ES,	FI,	GB,	GD,	GE,	GH,	GM,
		HR,	HU,	ID,	IL,	IN,	IS,	JP,	ΚE,	KG,	ΚP,	KR,	ΚZ,	LC,	LK,	LR,	LS,
		LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MZ,	NO,	ΝZ,	PL,	PT,	RO,
		RU,	SD,	SE,	SG,	SI,	SK,	SL,	ТJ,	TM,	TR,	TT,	ΤZ,	UA,	UG,	US,	UZ,
		•	YU,	•													
	RW:	GH,	GM,	KΕ,	LS,	MW,	ΜZ,	SD,	SL,	SZ,	ΤZ,	UG,	ZW,	ΑT,	BE,	CH,	CY,
		•	•		•	•		•	•	•	•	•	•	PT,	•	•	BF,
														SN,		ΤG	
	2417																
EP	1305																
	R:											LI,	LU,	NL,	SE,	MC,	PT,
22	0001					FI,						02F0		2001	0705		
	2001																
JP	2004	5043	9 /	T.	2	2004	0212		J :	2 20	02-5	1413	0	2001	0725		
	5237																
ZA NO	2003 2003	0003	09 15	A A		2004	0422		L/A	1 20	03-3	09 15		2003	0122		
	2003													2003			
110	6962	0309	90	A	2	2004	1100		U.	5 20	05-5	3302	9	2003	0020		
	2006								119	s 20	05-2	1914	R	2005	0902		
IORIT					L	2000	OIIJ		-					2000			
TORT	1 7111	ши.	11110	• •					_					2001			
														2001			
														2003			
													-				

Ι

AB (CH₂)
$$n-N$$

R1

 Z^{1}
 Z^{5}
 Z^{3}
 Z^{4}

dioxalate Br

AΒ Aminopiperidine quinoline compds. I (Z1-Z5 = one is N, one (or two independently are) CR1a and the remainder are CH; R1 and R1a = independently are H, OH, NH2, CONH2, halogen, (un) substituted S and SO2, (un) substituted alkyl and alkoxy, etc.; R2 = H, (un) substituted alkyl or alkenyl; R3 = H, CO2H, (un) substituted amino, etc.; R4 = CO, SO2, CH2 attached to an optionally substituted bicyclic, carbocyclic or heterocyclic ring system; n = 0-1; AB = substituted N or C), their salts and pharmaceutically acceptable derivs. were prepared and found to be useful in treating bacterial infections in mammals, especially humans. Thus II was prepared from 4-amino-1-[2-(R)-hydroxy-2-(6-methoxyquinolin-4yl)]ethylpiperidine and 5-bromo-1H-indole-2-carboxaldehyde and was determined to have an MIC less than or equal to $32\mu g/mL$ against one or more of gram pos. and neg. bacteria such as S. aureus Oxford and WCUH29 and S. pneumoniae 1629, N1387 and ERY 2.

MSTR 1

· ,

G1 = F / piperidino G6 = 42-1 39-3 34-66 35-67

G8 = imidazolyl

Patent location:

claim 1

Note: substitution is restricted

Note: additional ring formation also claimed

Note: also incorporates claim 13

11

Note: and precursors

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS

L19 ANSWER 10 OF 10 MARPAT COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER:

REFERENCE COUNT:

126:207509 MARPAT

TITLE:

Heterocyclic hypoxia-selective cytotoxins with

affinity for DNA, compound preparation, and usefulness

as chemosensitizers and radiosensitizers

INVENTOR(S):

Papadopoulou-Rosenzweig, Maria V.; Bloomer, William D.

Evanston Hospital Corporation, USA

PATENT ASSIGNEE(S):

U.S., 39 pp.

SOURCE:

CODEN: USXXAM

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

P.	ATENT NO.	K:	IND	DATE	API	PLICATION	NO.	DATE
_								
Ū	S 5602142	i	A	19970211	US	1994-3612	20	19941221
U	S 5958947	i	A	19990928	US	1996-7413	328	19961028
PRIORI	TY APPLN.	INFO.:			US	1994-3612	220	19941221
GI								

$$R^{1}$$
 E
 G
 N
 R^{4}
 E
 D
 R^{3}
 R^{2}
 $HN-(CH_{2}) n-N$
 N
 N
 NO_{2}

Hypoxia-selective cytotoxins I [D, E, F, G = C, N, provided that ≥ 3 AB of D, E, F and G are C; R1, R2 = Me, halo, H, CF3, MeO, CN, methylsulfo; R3, R4 = Me, Et, Ph, naphthyl, tert-Bu, halo, halomethylene, H, CF3, CN, methylsulfo, or R3 and R4 taken together are (un)substituted 5- or 6-membered nonarom. ring system; n = 1-5; X = C, N; Z = physiol. acceptable anion], are disclosed. The compds. are useful as radiosensitizers or chemosensitizers, especially in the treatment of cancer patients.

Ι

MSTR 2B

$$G1 = 4-7 5-10$$

disclosure